Belantamab Mafodotin
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 244 publications
Corneal Epithelial Thickness Alterations in Multiple Myeloma Patients Treated with Belantamab Mafodotin.
Journal: Seminars in ophthalmology
Published: August 11, 2026
A real-world pharmacovigilance analysis of cardiac adverse events associated with newer antibody-drug conjugates for hematological malignancies in adults: A disproportionality analysis from FDA adverse event reporting system database.
Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Published: July 31, 2026
Belantamab mafodotin, a BCMA-directed antibody-drug conjugate for multiple myeloma.
Journal: Future oncology (London, England)
Published: July 08, 2026
Exposure-response and dose simulation of belantamab mafodotin in combination with standards of care in patients with relapsed/refractory multiple myeloma.
Journal: Haematologica
Published: May 08, 2026
Comparative Efficacy of Belantamab Mafodotin in Combination With Bortezomib and Dexamethasone Versus Standards of Care in Patients With Third-Line or Later Relapsed/Refractory Multiple Myeloma.
Journal: American journal of hematology
Published: April 24, 2026
Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Patients With Relapsed/Refractory Multiple Myeloma Who Have Normal and Varying Degrees of Impaired Renal Function.
Journal: Clinical lymphoma, myeloma & leukemia
Published: April 10, 2026
Belantamab Mafodotin for Patients With Multiple Myeloma: Clinical Development and Practical Strategies for Dose Optimization and Toxicity Management.
Journal: Clinical lymphoma, myeloma & leukemia
Published: April 07, 2026
Cutaneous adverse events with antibody-drug conjugates: a FAERS-based pharmacovigilance study.
Journal: Frontiers in medicine
Published: April 03, 2026
A review of the clinical efficacy of monoclonal antibody (mAb)-based therapies for relapsed/refractory multiple myeloma (RRMM).
Journal: Expert opinion on biological therapy
Published: March 17, 2026
Current positioning and future development of belantamab mafodotin and other antibody-drug conjugates to treat multiple myeloma.
Journal: Frontiers in oncology
Published: March 03, 2026
The Evolution of Chimeric Antigen Receptor T-Cell, Bispecific Antibodies and Antibody-Drug Conjugates for the Treatment of Multiple Myeloma.
Journal: Clinical lymphoma, myeloma & leukemia
Published: February 06, 2026
Last Updated: 09/26/2026